Profile data is unavailable for this security.
About the company
BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) market. The Company facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, and distribution. Its CryoStor freeze media and HypoThermosol hypothermic storage media are optimized to preserve cells in the regenerative medicine market. Its Sexton cell processing product line includes human platelet lysates (hPL) for cell expansion. Its CellSeal cryogenic vials, which are rigid containers used in cell and gene therapy (CGT). Its CryoCase cryo-compatible transparent rigid containers are designed for closed-system fill and retrieval, and automated cell processing machines. The Company’s ThawSTAR product line is composed of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags.
- Revenue in USD (TTM)118.41m
- Net income in USD-26.44m
- Incorporated1998
- Employees409.00
- LocationBioLife Solutions IncSUITE 310, 3303 MONTE VILLA PARKWAYBOTHELL 98021United StatesUSA
- Phone+1 (425) 401-1400
- Fax+1 (425) 402-1433
- Websitehttps://www.biolifesolutions.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytek Biosciences Inc | 201.21m | -10.16m | 832.12m | 645.00 | -- | 2.17 | -- | 4.14 | -0.0782 | -0.0782 | 1.52 | 2.97 | 0.3982 | 1.60 | 3.72 | 297,647.90 | -2.01 | -- | -2.29 | -- | 54.92 | -- | -5.05 | -- | 5.47 | -- | 0.0083 | -- | 17.67 | -- | -571.58 | -- | -- | -- |
| Paragon 28 Inc | 245.00m | -63.08m | 870.95m | 430.00 | -- | 6.25 | -- | 3.55 | -0.7599 | -0.7599 | 2.95 | 1.67 | 0.823 | 0.6362 | 7.06 | 569,755.80 | -21.19 | -- | -25.76 | -- | 75.22 | -- | -25.75 | -- | 1.60 | -4.20 | 0.4424 | -- | 19.30 | -- | 28.94 | -- | -- | -- |
| CeriBell Inc | -100.00bn | -100.00bn | 898.43m | -- | -- | -- | -- | -- | -- | -- | -- | 0.336 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 2.14 | -- | 0.6304 | -- | 74.47 | -- | 20.72 | -- | -- | -- |
| Bioventus Inc | 555.06m | -39.48m | 934.09m | 1.03k | -- | 6.28 | -- | 1.68 | -0.6172 | -0.6172 | 8.68 | 1.83 | 0.7023 | 1.95 | 4.73 | 572,227.80 | -6.47 | -5.52 | -9.13 | -7.27 | 67.00 | 68.25 | -9.22 | -10.94 | 0.9866 | 1.13 | 0.6725 | -- | 0.0445 | 9.93 | 6.91 | -- | 23.51 | -- |
| Owens & Minor, Inc. | 10.66bn | -48.79m | 943.04m | 13.70k | -- | 1.08 | 4.26 | 0.0885 | -0.6346 | -0.6346 | 139.27 | 11.35 | 2.09 | 7.26 | 15.86 | 778,172.30 | -0.9561 | 1.32 | -1.49 | 2.07 | 20.72 | 16.48 | -0.4576 | 0.5614 | 0.4519 | 2.03 | 0.6831 | 0.798 | 3.80 | 1.87 | -284.47 | -- | 25.91 | -- |
| Pulse Biosciences Inc | 0.00 | -46.13m | 991.65m | 56.00 | -- | 12.53 | -- | -- | -0.8069 | -0.8069 | 0.00 | 1.29 | 0.00 | -- | -- | 0.00 | -58.03 | -93.21 | -62.84 | -104.99 | -- | -- | -- | -12,332.25 | -- | -- | 0.00 | -- | -100.00 | -- | 27.85 | -- | -15.20 | -- |
| BioLife Solutions Inc | 118.41m | -26.44m | 1.17bn | 409.00 | -- | 3.61 | -- | 9.89 | -0.5826 | -1.01 | 2.59 | 7.04 | 0.2987 | 1.69 | 5.58 | 289,513.40 | -6.67 | -13.76 | -7.37 | -15.04 | 46.15 | 36.76 | -22.33 | -42.99 | 1.78 | -4.03 | 0.0614 | -- | -11.43 | 48.65 | 52.49 | -- | 86.35 | -- |
| Artivion Inc | 384.90m | -846.00k | 1.18bn | 1.50k | -- | 3.85 | 51.37 | 3.05 | -0.0235 | -0.0235 | 9.25 | 7.27 | 0.4879 | 1.68 | 5.50 | 256,599.30 | -0.1079 | -2.20 | -0.1242 | -2.36 | 64.53 | 65.51 | -0.2211 | -5.34 | 1.33 | 1.10 | 0.51 | -- | 12.82 | 6.14 | -60.09 | -- | 5.13 | -- |
| Establishment Labs Holdings Inc | 153.07m | -70.61m | 1.19bn | 933.00 | -- | 36.43 | -- | 7.78 | -2.58 | -2.58 | 5.57 | 1.17 | 0.5534 | 0.7916 | 2.51 | 168,580.40 | -25.53 | -33.22 | -31.21 | -41.12 | 65.08 | 64.73 | -46.13 | -43.19 | 2.29 | -4.51 | 0.856 | -- | 2.13 | 21.96 | -4.38 | -- | 69.16 | -- |
| STAAR Surgical Co | 341.22m | 21.78m | 1.31bn | 1.06k | 60.78 | 3.06 | 47.44 | 3.85 | 0.4381 | 0.4381 | 6.90 | 8.69 | 0.6763 | 2.03 | 3.15 | 323,128.80 | 4.32 | 6.77 | 4.92 | 7.90 | 78.73 | 76.89 | 6.38 | 9.16 | 5.38 | -- | 0.0002 | 0.00 | 13.37 | 21.07 | -46.18 | 33.85 | 51.95 | -- |
| Adapthealth Corp | 3.26bn | -217.76m | 1.33bn | 10.70k | -- | 0.8776 | 8.07 | 0.4079 | -1.64 | -1.64 | 24.23 | 11.27 | 0.7096 | 21.15 | 8.45 | 304,912.50 | -4.57 | -4.34 | -5.14 | -4.89 | 19.03 | 18.28 | -6.44 | -6.47 | 0.9951 | 2.29 | 0.5757 | -- | 7.73 | -- | -1,169.99 | -- | -- | -- |
| Evolent Health Inc | 2.46bn | -104.23m | 1.35bn | 4.70k | -- | 1.28 | 92.72 | 0.5482 | -0.9129 | -0.9129 | 21.55 | 10.66 | 0.953 | -- | 6.14 | 524,309.40 | -2.79 | -9.60 | -3.58 | -12.59 | 15.96 | 24.50 | -2.93 | -13.66 | -- | -0.5595 | 0.3285 | -- | 45.26 | 25.65 | -660.71 | -- | -6.18 | -- |
| Myriad Genetics, Inc. | 823.60m | -116.00m | 1.38bn | 2.70k | -- | 1.88 | -- | 1.67 | -1.30 | -1.30 | 9.21 | 8.04 | 0.7385 | 9.91 | 6.84 | 305,037.00 | -10.40 | -- | -12.43 | -- | 69.15 | -- | -14.08 | -- | 1.73 | -105.00 | 0.0506 | -- | 11.03 | -- | -135.09 | -- | -- | -- |
| Inmode Ltd | 423.75m | 153.67m | 1.41bn | 581.00 | 10.01 | 2.07 | 9.14 | 3.33 | 1.85 | 1.85 | 5.04 | 8.92 | 0.5239 | 1.58 | 10.15 | 729,339.10 | 19.00 | 31.32 | 20.77 | 35.64 | 81.64 | 84.46 | 36.26 | 39.65 | 9.91 | -- | 0.00 | 0.00 | 8.32 | 37.49 | 22.54 | 54.65 | 13.10 | -- |
| Alphatec Holdings Inc | 572.74m | -177.87m | 1.45bn | 839.00 | -- | -- | -- | 2.53 | -1.27 | -1.27 | 4.08 | 0.1546 | 0.8089 | 1.11 | 7.73 | 682,644.80 | -25.12 | -30.97 | -32.00 | -39.47 | 69.47 | 66.02 | -31.06 | -46.22 | 1.15 | -3.66 | 0.9596 | -- | 37.45 | 39.38 | -23.36 | -- | 67.92 | -- |
Data as of Nov 21 2024. Currency figures normalised to BioLife Solutions Inc's reporting currency: US Dollar USD
57.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Casdin Capital LLCas of 30 Sep 2024 | 8.71m | 18.77% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 5.16m | 11.13% |
| Invesco Advisers, Inc.as of 30 Sep 2024 | 3.03m | 6.53% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.75m | 5.93% |
| Fred Alger Management LLCas of 30 Sep 2024 | 1.58m | 3.40% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 1.41m | 3.05% |
| William Blair Investment Management LLCas of 30 Sep 2024 | 1.15m | 2.48% |
| Cramer Rosenthal McGlynn LLCas of 30 Sep 2024 | 1.10m | 2.38% |
| Geneva Capital Management LLCas of 30 Sep 2024 | 865.27k | 1.87% |
| Geode Capital Management LLCas of 30 Sep 2024 | 842.77k | 1.82% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
